Patient Square Capital, a dedicated health care investment firm, led a $100m Series B round in Kriya Therapeutics, a fully integrated platform company pioneering novel technologies and therapeutics in gene therapy, with participation from new investors Woodline Partners, CAM Capital, Hongkou, Alumni Ventures and others. All existing institutional investors also participated in this round, including QVT, Dexcel Pharma, Foresite Capital, Bluebird Ventures, Transhuman Capital, Narya Capital, Amplo and JDRF. “Kriya was formed with the mission of revolutionizing how gene therapies are designed, developed and produced by fully integrating advanced manufacturing technologies, computational tools and development capabilities within a single company. With the support of our new and existing investors, we believe that Kriya is well positioned to deliver transformative improvements in cost, scale and efficiency that will help the gene therapy field achieve its full potential across a range of therapeutic areas,” Shankar Ramaswamy, Kriya Therapeutics Co-Founder and Chief Executive Officer.